Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis

References

• 1. Hoang-Xuan K, Deckert M, Ferreri A et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro-Oncology. 25(1), 37–53 (2022).
  Google Scholar
• 2. Grommes C, DeAngelis LM. Primary CNS lymphoma. J. Clin. Oncol. 35(21), 2410–2418 (2017).
  Medline CASGoogle Scholar
• 3. O'Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am. J. Hematol. 88(12), 997–1000 (2013).
  MedlineGoogle Scholar
• 4. Ostrom QT, Gittleman H, Liao P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-Oncology 16(Suppl. 4), iv1–iv63 (2014).
  MedlineGoogle Scholar
• 5. Savina M, Gourgou S, Italiano A et al. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review. Crit. Rev. Oncol. Hemat. 123, 21–41 (2018).
  MedlineGoogle Scholar
• 6. Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F. Endpoints in cancer clinical trials. J. Visc. Surg. 151(1), 17–22 (2014).
  Medline CASGoogle Scholar
• 7. Gion M, Pérez-García JM, Llombart-Cussac A, Sampayo-Cordero M, Cortés J, Malfettone A. Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Ther. Adv. Med. Oncol. 13, 17495677 (2021).
  Google Scholar
• 8. Zhu J, Yang Y, Tao J et al. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia 34(10), 2576–2591 (2020).
  Medline CASGoogle Scholar
• 9. Shi Q, Schmitz N, Ou FS et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J. Clin. Oncol. 36(25), 2593–2602 (2018).
  Medline CASGoogle Scholar
• 10. US FDA. Table of surrogate endpoints that were the basis of drug approval licensure. www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure (Accessed 2 October 2022).
  Google Scholar
• 11. Tannock IF, Pond GR, Booth CM. Biased evaluation in cancer drug trials-how use of progression-free survival as the primary end point can mislead. JAMA Oncol. 8(5), 679–680 (2022).
  MedlineGoogle Scholar
• 12. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ Brit. Med. J. 372, n71 (2021).
  Google Scholar
• 13. Ferreri AJM, Reni M, Foppoli M et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374(9700), 1512–1520 (2009).
  Medline CASGoogle Scholar
• 14. Mead GM, Bleehen NM, Gregor A et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Am. Cancer Soc. 89(6), 1359–1370 (2000).
  CASGoogle Scholar
• 15. Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ Brit. Med. J. 343, d5928 (2011).
  Google Scholar
• 16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007).
  MedlineGoogle Scholar
• 17. Xie W, Halabi S, Tierney JF et al. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spect. 3(1), kz2 (2019).
  Google Scholar
• 18. Ferreri A, Cwynarski K, Pulczynski E et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 36(7), 1870–1878 (2022).
  Medline CASGoogle Scholar
• 19. Mishima KNRN, Fukuda H. Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C. J. Clin. Oncol. 38(Suppl. 15), 2500 (2020).
  Google Scholar
• 20. Bromberg JEC, Issa S, Bakunina K et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 20(2), 216–228 (2019).
  Medline CASGoogle Scholar
• 21. Houillier CTLD, Soussain C. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J. Clin. Oncol. 37(10), 823–833 (2019).
  Medline CASGoogle Scholar
• 22. Wu JDLZ, Zhang M. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. J. Neurooncol. 140(2), 427–434 (2018).
  Medline CASGoogle Scholar
• 23. Omuro A, Chinot O, Taillandier L et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2(6), e251–e259 (2015).
  MedlineGoogle Scholar
• 24. Korfel A, Thiel E, Martus P et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 84(12), 1242–1248 (2015).
  Medline CASGoogle Scholar
• 25. Holdhoff M, Wagner-Johnston N, Roschewski M. Systemic approach to recurrent primary CNS lymphoma: perspective on current and emerging treatment strategies. Oncotargets Ther. 13, 8323–8335 (2020).
  Medline CASGoogle Scholar
• 26. Tao K, Wang X, Tian X. Relapsed primary central nervous system lymphoma: current advances. Front Oncol. 11, 649789 (2021).
  Medline CASGoogle Scholar
• 27. Del PJ, Berry JS, Hopman WM et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 7(5), 728–734 (2021).
  MedlineGoogle Scholar
• 28. Bonm AV, Gibson AW, Holmberg LA et al. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma. J. Neurooncol. 151(2), 193–200 (2021).
  Medline CASGoogle Scholar
• 29. Langner-Lemercier S, Houillier C, Soussain C et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncology 18(9), 1297–1303 (2016).
  MedlineGoogle Scholar
• 30. Du P, Chen H, Shen L et al. Analysis of key factors associated with response to salvage high-dose methotrexate rechallenge in primary central nervous system lymphoma with first relapse. Curr. Oncol. 29(9), 6642–6656 (2022).
  MedlineGoogle Scholar
• 31. Grommes C, Tang SS, Wolfe J et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 133(5), 436–445 (2019).
  Medline CASGoogle Scholar
• 32. Ghesquieres H, Chevrier M, Laadhari M et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann. Oncol. 30(4), 621–628 (2019).
  Medline CASGoogle Scholar
• 33. Nayak L, Iwamoto FM, LaCasce A et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129(23), 3071–3073 (2017).
  Medline CASGoogle Scholar
• 34. Alcantara M, Houillier C, Blonski M et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood 139(5), 792–796 (2022).
  Medline CASGoogle Scholar
• 35. Zhang Z, Fan Q, Luo X, Lou K, Weiss WA, Shokat KM. Brain-restricted mTOR inhibition with binary pharmacology. Nature 609(7928), 822–828 (2022).
  Medline CASGoogle Scholar
• 36. Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J. Clin. Oncol. 23(22), 5034–5043 (2005).
  MedlineGoogle Scholar
• 37. Zhang Y, Zou D, Yin J et al. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma. BMC Cancer 21(1), 183 (2021).
  MedlineGoogle Scholar